Why the study?
Does the Cryolife O'Brien stentless bioprosthesis provide satisfactory clinical and hemodynamic outcomes in patients aged >75 years requiring aortic valve replacement?
Does the Cryolife O'Brien stentless bioprosthesis provide satisfactory clinical and hemodynamic outcomes in patients aged >75 years requiring aortic valve replacement?
The Cryolife O'Brien stentless bioprosthesis demonstrates excellent 7-year survival and favorable hemodynamic remodeling in elderly patients undergoing aortic valve replacement.
Answers are grounded in this paper and cite their sources.
Supports stentless bioprosthesis use in elderly AVR; extends observational data but leaves comparative efficacy open.
Objective. Seven-year clinical and hemodynamic results of the Cryolife O'Brien (CLOB) stentless bioprosthesis in elderly patients are reported. Methods. From 1993 to 2000, 36 patients aged >75 years had a CLOB implanted in the aortic position. Eighteen (50%) were male. All patients were monitored with serial echocardiograms performed preoperatively, at discharge, six months, one year and yearly thereafter. Results. The 30-day mortality was 2.4% (1/36). Actuarial survival at one, five and seven years were 96.7±1.5. 94.8±2.0 and 94.8±2.0%, respectively. Peak and mean gradients (PG and MG) reduced and effective orifice area index (EOAI) increased over time ( P<0.001). Left ventricular mass index (LVMI) reduced by 32 g/m2 at discharge ( P<0.001) and by 33 g/m2 at six months ( P<0.001) without further significant changes. Conclusions. In our series CLOB xenograft resulted to be a satisfactory valve substitute in elderly patients.
No takes yet. Share an insight, caveat, or question.
Gelsomino et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: